With extended applications, Tapestri Designer, the only AI-powered cloud-based tool for single-cell panel designs, will improve drug development and CRISPR quality control studies
Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, today announced extended capabilities for Tapestri Designer, the first-ever automated, cloud-based tool for designing targeted single-cell DNA custom panels. Now with applications across mouse genomes and CRISPR editing, the product’s easy to use, AI-powered, self-service interface reduces design time for custom panels from weeks to just minutes to help accelerate cell and gene therapy.
In order to realize the potential of gene editing technologies and CRISPR-based therapies, it’s critical to have tools to track the intended DNA edits, along with measuring what unintended changes may have also occurred. Similarly, in the development of new treatments, leveraging model organisms, like mouse models, provides the opportunity to test possible therapeutic agents and evaluate their precise effects in preclinical drug development phases.
“With Tapestri Designer, research teams have the flexibility to quickly and easily target relevant regions of interest at the single-cell level — keeping analysis simple and cost-effective — while increasing speed and efficiency for high-impact applications,” explained Anup Parikh, Ph.D., VP of Software and Informatics at Mission Bio. “With these extended capabilities, we’re further supporting cell and gene therapy applications across academia and pharma to accelerate more precise, impactful treatments to market.”
The Tapestri Platform is the first and only single-cell multi-omic platform capable of detecting DNA and protein changes simultaneously from the same cell, and Tapestri Designer has already been used to design hundreds of custom panels across a variety of cancer applications. The update extends the best-in-class Tapestri Designer to further support researchers with:
- CRISPR applications: Researchers can uniquely measure zygosity, co-occurrence of multiple edits including on- and off-target events, and rare cell populations, providing the information necessary to optimize editing systems and use them safely.
- Mouse genome compatibility: Critical to advancing pre-clinical and early phases of drug development programs, mouse single-cell custom DNA panels are now available.
- White glove service: Mission Bio design experts are on-hand to support customers with unique and novel custom panel needs for single-cell DNA or multi-omics panels.
“As I want to maximize the data from a single cell sequencing study of rare patient samples, it is imperative that the targeted panel is built wisely,” explained Guy Ledergor, MD, PhD, at the University of California, San Francisco. “Tapestri Designer does just that – with an easy to use interface, and high coverage of my genomic regions of interest.”
This latest milestone comes on the heels of a landmark year for Mission Bio’s work to support treatment development and accelerate clinical trials. Agios and several leading research institutions have leveraged the Tapestri Platform to support efforts to improve cancer research, accelerate drug development, and optimize treatment for patients. To learn more about Tapestri Designer updates, register for this webinar on Tuesday June 2, 2020.
About Mission Bio
Mission Bio delivers targeted solutions for high impact applications with the Tapestri Platform. The Tapestri Platform is the industry’s first and only single-cell multi-omics platform, enabling genotype and phenotype from the same cell, and precise detection of heterogeneity in disease progression and treatment response. Application areas include blood cancers, solid tumors, and genome editing validation.
Researchers at Stanford University, MD Anderson Cancer Center (MDACC), the University of California at San Francisco (UCSF) and the University of Pennsylvania (Penn) have all leveraged the Tapestri Platform to support their research for characterizing clonal dynamics in AML, identifying MRD, and monitoring treatment response and therapy resistance. The company’s award-winning technology is also leveraged by LabCorp and Onconova Therapeutics to enable more efficient clinical trials.0